Telix Pharmaceuticals Limited (ASX:TLX)

Australia flag Australia · Delayed Price · Currency is AUD
14.52
-0.59 (-3.90%)
Oct 13, 2025, 1:45 PM AEST
-3.90%
Market Cap5.11B
Revenue (ttm)1.01B
Net Income (ttm)16.54M
Shares Out338.40M
EPS (ttm)0.07
PE Ratio232.32
Forward PE153.09
Dividendn/a
Ex-Dividend Daten/a
Volume1,178,762
Average Volume2,489,545
Open14.95
Previous Close15.11
Day's Range14.52 - 14.95
52-Week Range13.30 - 31.97
Beta2.27
RSI44.20
Earnings DateOct 16, 2025

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 234
Stock Exchange Australian Securities Exchange
Ticker Symbol TLX
Full Company Profile

Financial Performance

In 2024, Telix Pharmaceuticals's revenue was $484.69 million, an increase of 41.49% compared to the previous year's $342.57 million. Earnings were $30.89 million, an increase of 769.68%.

Financial numbers in USD Financial Statements

News

Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLX

NEW YORK , Oct. 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuticals...

2 days ago - PRNewsWire

TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceutic...

4 days ago - GlobeNewsWire

TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceutic...

7 days ago - GlobeNewsWire

Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLX

NEW YORK , Oct. 3, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuticals...

9 days ago - PRNewsWire

TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceutic...

10 days ago - GlobeNewsWire

TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuti...

13 days ago - GlobeNewsWire

Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLX

NEW YORK , Sept. 28, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceutical...

14 days ago - PRNewsWire

TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuti...

16 days ago - GlobeNewsWire

TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, Sept. 23, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuti...

19 days ago - GlobeNewsWire

CMS Grants Transitional Pass-Through Status for Gozellix

MELBOURNE, Australia and INDIANAPOLIS, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Centers for Medic...

19 days ago - GlobeNewsWire

Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLX

NEW YORK , Sept. 22, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceutical...

20 days ago - PRNewsWire

ASX 200 LIVE: Shares rise as gold stocks jump; Myer plunges 17pc

Shares open higher; Nvidia rallies; gold price resets record; Myer profits tumble; Telix Pharmaceuticals jumps 10 per cent. Follow live.

20 days ago - The Australian Financial Review

TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, Sept. 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuti...

22 days ago - GlobeNewsWire

Telix Pharmaceuticals Limited (TLX) Hits Another Roadblock After SEC Subpoena, Shares Fall Again -- Hagens Berman

SAN FRANCISCO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- On August 28, 2025, investors in Telix Pharmaceuticals Limited (NASDAQ: TLX) saw the price of their American Depositary Shares fall about 16% after th...

23 days ago - GlobeNewsWire

TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuti...

26 days ago - GlobeNewsWire

Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLX

NEW YORK , Sept. 15, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceutical...

27 days ago - PRNewsWire

TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Telix Pharmaceuticals Limited on Behalf of Telix Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Telix (TLX) To Contact Him Directly To Discuss Their Options If you purchased or acquired st...

27 days ago - GlobeNewsWire

TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Telix Pharmaceuticals Limited on Behalf of Telix Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Telix (TLX) To Contact Him Directly To Discuss Their Options If you purchased or acquired st...

4 weeks ago - GlobeNewsWire

TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuti...

4 weeks ago - GlobeNewsWire

Telix Pharmaceuticals Limited (TLX) Hits Another Roadblock After SEC Subpoena, Shares Fall Again – Hagens Berman

SAN FRANCISCO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- On August 28, 2025, investors in Telix Pharmaceuticals Limited (NASDAQ: TLX) saw the price of their American Depositary Shares fall about 16% after th...

4 weeks ago - GlobeNewsWire

Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLX

NEW YORK , Sept. 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceutical...

4 weeks ago - PRNewsWire

Telix Pharmaceuticals Limited (TLX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Telix Pharmaceuticals Limited (NASDAQ:TLX) H.C. Wainwright 27th Annual Global Investment Conference September 9, 2025 12:00 PM EDT Company Participants Christian Behrenbruch - Co-Founder, MD, Group C...

4 weeks ago - Seeking Alpha

Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis

MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has dosed the first patient in a Phase 3 cli...

4 weeks ago - GlobeNewsWire

TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, Sept. 07, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuti...

5 weeks ago - GlobeNewsWire